Five months after completing the acquisition of Dendreon Corp., Chinese conglomerate Sanpower Group has taken a substantial step toward making real progress with the heart of the deal, Provenge (sipuleucel-T), as it is preparing to file the drug registration with the Pharmacy and Poisons Board of Hong Kong, the first move to advance the immunotherapy’s development in Asia.
Through a Hong Kong entity, Dendreon HK Limited, Sanpower finished the acquisition of a manufacturing facility in Wong Chuk Hang...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

